Evidence map›Paper›PMID 35893842›Full record

ArticleToxics2022

Antiseizure and Neuroprotective Efficacy of Midazolam in Comparison with Tezampanel (LY293558) against Soman-Induced Status Epilepticus.

Taiza H Figueiredo, Vassiliki Aroniadou-Anderjaska, Volodymyr I Pidoplichko, James P Apland, Maria F M Braga

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Taiza H FigueiredoDepartment of Anatomy, Physiology, and Genetics, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Vassiliki Aroniadou-AnderjaskaDepartment of Anatomy, Physiology, and Genetics, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Volodymyr I PidoplichkoDepartment of Anatomy, Physiology, and Genetics, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
James P AplandNeuroscience Branch, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Aberdeen, MD 21010, USA.
Maria F M BragaDepartment of Anatomy, Physiology, and Genetics, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Uniformed Services University of the Health Sciences · USUnited States Army · US

Funding

Antiglutamatergic Therapy to Protect the Immature Brain Against Nerve AgentsU01NS102135 · NINDS · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI BRAGA, MARIA F. · 2018 to 2020
$1.3M
Targeting the Glutamatergic System to Counteract Soman Toxicity in Immature RatsR21NS094131 · NINDS · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI BRAGA, MARIA F. · 2015 to 2016
$744k
NIH HHS 5R21NS094131-02 and 1U01NS102135-01A1NINDS NIH HHS R21 NS094131NINDS NIH HHS U01 NS102135
6 · The paper itself

Abstract

Acute exposure to nerve agents induces status epilepticus (SE), which can cause death or long-term brain damage. Diazepam is approved by the FDA for the treatment of nerve agent-induced SE, and midazolam (MDZ) is currently under consideration to replace diazepam. However, animal studies have raised questions about the neuroprotective efficacy of benzodiazepines. Here, we compared the antiseizure and neuroprotective efficacy of MDZ (5 mg/kg) with that of tezampanel (LY293558; 10 mg/kg), an AMPA/GluK1 receptor antagonist, administered 1 h after injection of the nerve agent, soman (1.2 × LD

Indexed as

amygdalamidazolamneuroprotectionseizuressomantezampanel

Identifiers

PMID35893842
PMCPMC9330837
OpenAlexW4287219819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.